Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate the HLX10 Monotherapy for the Treatment of Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors That Failed to Respond to Standard Therapy

Next Previous
Trial Profile

A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate the HLX10 Monotherapy for the Treatment of Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors That Failed to Respond to Standard Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serplulimab (Primary)
  • Indications Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 19 Oct 2022 Results published in the British Journal of Cancer
  • 07 Jun 2022 Results (n=108; data cut off date- July 10, 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 25 Mar 2022 According to a Henlius Biopharmaceuticals media release, the National Medical Products Administration (NMPA), China, approved serplulimab injection (Hansizhuang) for the treatment of unresectable or metastatic microsattelite instability high (MSI-H) solid tumours, that have failed to respond to standard therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top